% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lehtinen:286744,
author = {M. Lehtinen and L. Bruni and M. Elfström and P. Gray and
M. Logel and F. C. Mariz$^*$ and I. Baussano and S. Vänskä
and E. L. Franco and J. Dillner},
title = {{S}cientific approaches toward improving cervical cancer
elimination strategies.},
journal = {International journal of cancer},
volume = {154},
number = {9},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2024-00077},
pages = {1537-1548},
year = {2024},
note = {2024 May 1;154(9):1537-1548},
abstract = {At the 2023 EUROGIN workshop scientific basis for
strategies to accelerate the elimination of cervical cancer
and its causative agent, human papillomavirus (HPV) were
reviewed. Although some countries have reached key
performance indicators toward elimination $(>90\%$ of girls
HPV vaccinated and $>70\%$ of women HPV screened), most are
yet to reach these targets, implying a need for improved
strategies. Gender-neutral vaccination, even with moderate
vaccination coverage was highlighted as a strategy to
achieve elimination more rapidly. It is more resilient
against major disturbances in vaccination delivery, such as
what happened during the coronavirus pandemic. Further, an
analysis of ethical/legal issues indicated that
female-restricted vaccination is problematic. Extended
catch-up of vaccination with concomitant screening, and
outreach to vulnerable groups were highlighted. Although
birth cohorts with high coverage of HPV vaccination at
school are protected against HPV, and HPVs have a very low
reproductive rate in women above age 35, adult women below
age 30 have inadequate direct protection. In addition to
herd protection from gender-neutral vaccination, this group
can be protected by offering concomitant catch-up HPV
vaccination and HPV screening. Furthermore, hepatitis B
vaccination experiences indicate that elimination cannot be
achieved without prioritizing vulnerable/migrant
populations. The long-lasting durability of
vaccination-induced antibody responses suggests prolonged
protection with HPV vaccines when adequately administrated.
Finally, cost-effectiveness modelling suggests that
high-coverage HPV vaccination in multiple population
segments will be resource-saving due to reduced need for
screening. In summary, the workshop found that strategically
optimal deployment of vaccination will accelerate
elimination of HPV and cervical cancer.},
keywords = {HPV (Other) / gender-neutral (Other) / population immunity
(Other) / screening (Other) / vaccination (Other)},
cin = {F035 / D335},
ddc = {610},
cid = {I:(DE-He78)F035-20160331 / I:(DE-He78)D335-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38196123},
doi = {10.1002/ijc.34839},
url = {https://inrepo02.dkfz.de/record/286744},
}